Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Alnylam Pharmaceuticals, Inc. : Alnylam to Webcast Presentation at Upcoming Investor Conferences

09/03/2013 | 04:00pm EST

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013 at 11:10 a.m. ET at the Grand Hyatt in New York City.

In addition, Alnylam management will present a company overview at the Stifel 2013 Healthcare Conference on Thursday, September 12, 2013 at 10:55 a.m. ET at the Four Seasons Hotel in Boston.

A live audio webcast of the presentations will be available on the News & Investors section of the company's website, www.alnylam.com. A replay of the presentation will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. These include: ALN-TTR02, an intravenously delivered RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP); ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting TTR for the treatment of ATTR in patients with familial amyloidotic cardiomyopathy (FAC); ALN-AT3, an RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD); ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria (AIP); ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; ALN-TMP, an RNAi therapeutic targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-AAT, an RNAi therapeutic targeting alpha-1-antitrypsin (AAT) for the treatment of AAT deficiency liver disease; and ALN-CC5, an RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases, amongst other programs. As part of its "Alnylam 5x15TM" strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in clinical development, including programs in advanced stages, on its own or with a partner by the end of 2015. Alnylam has additional partnered programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection and ALN-VSP for the treatment of liver cancers. The company's leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist, Ascletis, Monsanto, Genzyme, and The Medicines Company. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for applications in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam's VaxiRNA TM platform applies RNAi technology to improve the manufacturing processes for vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world's top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, and the New England Journal of Medicine. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit www.alnylam.com.

Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
Vice President, Investor Relations and Corporate Communications
or
Spectrum (Media)
Amanda Sellers, 202-955-6222 x2597


ę Business Wire 2013
All news about ALNYLAM PHARMACEUTICALS, INC.
09:16aAlnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran ..
AQ
01/14Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran ..
BU
01/14Alnylam Pharmaceuticals, Inc. to Present Full 18-Month Results from the HELIOS-A Phase ..
CI
01/10Alnylam Announces Preliminary Fourth Quarter and Full Year 2021 Global Net Product Reve..
AQ
01/10ALNYLAM PHARMACEUTICALS : Announces Preliminary* Fourth Quarter and Full Year 2021 Global ..
PU
01/10Alnylam Pharmaceuticals Reports Higher Preliminary 2021 Net Product Revenue
MT
01/09Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Rev..
BU
01/06Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Li..
BU
01/06Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Li..
CI
01/06Novartis, Alnylam Collaborate on Liver-Targeted Therapy
MT
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 820 M - -
Net income 2021 -762 M - -
Net cash 2021 1 321 M - -
P/E ratio 2021 -23,0x
Yield 2021 -
Capitalization 17 761 M 17 761 M -
EV / Sales 2021 20,0x
EV / Sales 2022 13,3x
Nbr of Employees 1 453
Free-Float 99,4%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 148,50 $
Average target price 207,10 $
Spread / Average Target 39,5%
EPS Revisions
Managers and Directors
Yvonne L. Greenstreet Chief Executive Officer & Director
Akshay K. Vaishnaw President
Jeffrey V. Poulton Executive VP, Chief Financial & Accounting Officer
Michael W. Bonney Executive Chairman
Pushkal Garg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ALNYLAM PHARMACEUTICALS, INC.-12.43%17 761
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684